Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Facilitating clinical implementation of pharmacogenomics.

Literature DB >> 21771991

Facilitating clinical implementation of pharmacogenomics.

David A Mrazek¹, Caryn Lerman.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2011 PMID： 21771991 PMCID： PMC3189505 DOI： 10.1001/jama.2011.1010

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

× No keyword cloud information.

9 in total

1. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors: M V Relling; T E Klein
Journal: Clin Pharmacol Ther Date: 2011-01-26 Impact factor: 6.875

2. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors: Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal: JAMA Date: 2003-09-24 Impact factor: 56.272

3. Medical genetics: a marker for Stevens-Johnson syndrome.

Authors: Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal: Nature Date: 2004-04-01 Impact factor: 49.962

Review 4. Pharmacogenetics of antidepressant response.

Authors: Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal: J Psychiatry Neurosci Date: 2011-03 Impact factor: 6.186

Review 5. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?

Authors: A E Shields; C Lerman
Journal: Clin Pharmacol Ther Date: 2008-03-05 Impact factor: 6.875

Review 6. Clinical trials design lessons from the CATIE study.

Authors: Helena Chmura Kraemer; Ira D Glick; Donald F Klein
Journal: Am J Psychiatry Date: 2009-10-01 Impact factor: 18.112

7. Pharmacogenomics: "noninferiority" is sufficient for initial implementation.

Authors: R B Altman
Journal: Clin Pharmacol Ther Date: 2011-03 Impact factor: 6.875

8. Training in psychiatric genomics during residency: a new challenge.

Authors: Joel G Winner; Deborah Goebert; Courtenay Matsu; David A Mrazek
Journal: Acad Psychiatry Date: 2010 Mar-Apr

9. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.

Authors: F R Sallee; C L DeVane; R E Ferrell
Journal: J Child Adolesc Psychopharmacol Date: 2000 Impact factor: 2.576

9 in total

25 in total

Review 10. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?

Authors: Kyle J Burghardt; Vicki L Ellingrod
Journal: Mol Diagn Ther Date: 2013-02 Impact factor: 4.074

Facilitating clinical implementation of pharmacogenomics.

1. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

2. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

3. Medical genetics: a marker for Stevens-Johnson syndrome.

Review 4. Pharmacogenetics of antidepressant response.

Review 5. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?

Review 6. Clinical trials design lessons from the CATIE study.

7. Pharmacogenomics: "noninferiority" is sufficient for initial implementation.

8. Training in psychiatric genomics during residency: a new challenge.

9. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.

1. Pharmacogenetic testing: Current Evidence of Clinical Utility.

2. Ethical and practical challenges to studying patients who opt out of large-scale biorepository research.

3. Documenting Pharmacogenomic Testing with CPT Codes.

4. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

5. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.

Review 6. Genotype-based clinical trials in cardiovascular disease.

7. Physician response to implementation of genotype-tailored antiplatelet therapy.

8. Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.

9. Polygenic Risk of Spasmodic Dysphonia is Associated With Vulnerable Sensorimotor Connectivity.

Review 10. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?